Immunic (IMUX) will present four abstracts on vidofludimus calcium at the MSToronto2026 ACTRIMS-ECTRIMS meeting Oct 21-23. Data include Phase 2 CALLIPER open-label extension disability outcomes, preclinical Nurr1 mechanism, EBV-related cognitive effects, and a novel disability endpoint.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
